AR122718A1 - Formulaciones - Google Patents
FormulacionesInfo
- Publication number
- AR122718A1 AR122718A1 ARP210101730A ARP210101730A AR122718A1 AR 122718 A1 AR122718 A1 AR 122718A1 AR P210101730 A ARP210101730 A AR P210101730A AR P210101730 A ARP210101730 A AR P210101730A AR 122718 A1 AR122718 A1 AR 122718A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- dispersible tablet
- dolutegravir
- acceptable salt
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulación del comprimido dispersable caracterizada porque comprende dolutegravir o una sal farmacéuticamente aceptable del mismo y un ión farmacéuticamente aceptable. Reivindicación 11: El proceso para hacer una formulación del comprimido dispersable de conformidad con cualquiera de las reivindicaciones anteriores, caracterizado porque comprende mezclar dolutegravir o una sal farmacéuticamente aceptable del mismo y un ión farmacéuticamente aceptable. Reivindicación 14: El método de tratamiento de la infección por el VIH, caracterizado porque comprende la administración a dicho paciente de una formulación del comprimido dispersable como se reivindica con cualquiera de las reivindicaciones 1 a 10.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2009684.8A GB202009684D0 (en) | 2020-06-26 | 2020-06-26 | Formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122718A1 true AR122718A1 (es) | 2022-09-28 |
Family
ID=71949817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101730A AR122718A1 (es) | 2020-06-26 | 2021-06-23 | Formulaciones |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230285307A1 (es) |
EP (1) | EP4171572A1 (es) |
JP (1) | JP2023531086A (es) |
KR (1) | KR20230028288A (es) |
CN (1) | CN115697344A (es) |
AR (1) | AR122718A1 (es) |
AU (1) | AU2021296506A1 (es) |
BR (1) | BR112022026243A2 (es) |
CA (1) | CA3180544A1 (es) |
CL (1) | CL2022003743A1 (es) |
GB (1) | GB202009684D0 (es) |
IL (1) | IL298353A (es) |
MX (1) | MX2022015438A (es) |
TW (1) | TW202216154A (es) |
WO (1) | WO2021260567A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114191404B (zh) * | 2022-01-10 | 2023-06-27 | 安徽贝克生物制药有限公司 | 一种多替拉韦片剂及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2897137A1 (en) * | 2013-02-18 | 2014-08-21 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of dolutegravir |
WO2014184553A1 (en) * | 2013-05-15 | 2014-11-20 | Cipla Limited | Pharmaceutical antiretroviral compositions |
WO2015140569A1 (en) * | 2014-03-20 | 2015-09-24 | Cipla Limited | Pharmaceutical composition |
US10730888B2 (en) * | 2015-02-06 | 2020-08-04 | Mylan Laboratories Limited | Process for the preparation of dolutegravir |
HRP20240309T1 (hr) * | 2015-10-14 | 2024-05-10 | The Global Alliance For Tb Drug Development, Inc. | Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid |
-
2020
- 2020-06-26 GB GBGB2009684.8A patent/GB202009684D0/en not_active Ceased
-
2021
- 2021-06-23 CN CN202180043595.7A patent/CN115697344A/zh active Pending
- 2021-06-23 BR BR112022026243A patent/BR112022026243A2/pt unknown
- 2021-06-23 WO PCT/IB2021/055533 patent/WO2021260567A1/en unknown
- 2021-06-23 MX MX2022015438A patent/MX2022015438A/es unknown
- 2021-06-23 TW TW110122867A patent/TW202216154A/zh unknown
- 2021-06-23 EP EP21737779.5A patent/EP4171572A1/en active Pending
- 2021-06-23 US US18/001,635 patent/US20230285307A1/en active Pending
- 2021-06-23 KR KR1020227044459A patent/KR20230028288A/ko unknown
- 2021-06-23 AR ARP210101730A patent/AR122718A1/es unknown
- 2021-06-23 IL IL298353A patent/IL298353A/en unknown
- 2021-06-23 CA CA3180544A patent/CA3180544A1/en active Pending
- 2021-06-23 AU AU2021296506A patent/AU2021296506A1/en active Pending
- 2021-06-23 JP JP2022580247A patent/JP2023531086A/ja active Pending
-
2022
- 2022-12-23 CL CL2022003743A patent/CL2022003743A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021296506A1 (en) | 2023-01-05 |
GB202009684D0 (en) | 2020-08-12 |
US20230285307A1 (en) | 2023-09-14 |
EP4171572A1 (en) | 2023-05-03 |
CL2022003743A1 (es) | 2023-06-30 |
KR20230028288A (ko) | 2023-02-28 |
CN115697344A (zh) | 2023-02-03 |
TW202216154A (zh) | 2022-05-01 |
IL298353A (en) | 2023-01-01 |
WO2021260567A1 (en) | 2021-12-30 |
MX2022015438A (es) | 2023-03-22 |
BR112022026243A2 (pt) | 2023-01-17 |
JP2023531086A (ja) | 2023-07-20 |
CA3180544A1 (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2023000187A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
AR048439A1 (es) | Composiciones farmaceuticas y metodos para tratar la infeccion por vih | |
CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
PH12018502634A1 (en) | Topical compositions of apremilast | |
AR048324A1 (es) | Metodos para tratar infecciones por vih | |
BR112017027811A2 (pt) | conjugados específicos de inibidores de ksp | |
MX2021005421A (es) | Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos. | |
AR122718A1 (es) | Formulaciones | |
ES2174921T3 (es) | Inhibidores de la proteasa del vih. | |
CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
CY1125075T1 (el) | Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων | |
MX2022007911A (es) | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. | |
CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
MX2023004188A (es) | Compuestos fosfolipidos y usos de estos. | |
MX2021005423A (es) | Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos. | |
MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
MX2021015441A (es) | Formas cristalinas de cabotegravir de sodio. | |
DOP2023000084A (es) | Formulación sólida | |
AR122720A1 (es) | Una formulación de comprimidos dispersables | |
TR201908007T4 (tr) | Hıv enfeksiyonlarının tedavi edilmesine yönelik farmasötik bileşim. | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
MX2022012165A (es) | Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19. | |
MX2022015232A (es) | Composicion farmaceutica acuosa de levilimab y su uso. | |
EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
BR112022003126A2 (pt) | Conjugado terapêutico |